Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5373_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
19 Мб
Скачать
12 PEGylated Nanocarriers forDiagnostic Applications
Fig. 12.1 Prevention of opsonization by surface modication of nanocarriers with PEG
347
binding, non-covalent entrapment, or adsorption of PEG onto a product and is a common term for PEG modication (Van Vlerken etal. 2007).
A highly effective strategy for enhancing therapeutic drug systemic distribution is the PEGylation of nanoparticles (NPs). PEGylation of NPs has also been employed as a method to cross-extracellular barriers related to alternative adminis­tration methods, such as distribution to the mucosa or delivery to the brain. PEG coatings will undoubtedly remain an integral component in the design of NPs for drug and gene delivery applications, enabling more research to understand how the characteristics of PEG coating affect NPs biodistribution and removal from the body.
As more NP-based products are being used in the clinical setting, it is unclear what role the emerging PEG alternatives will play. However, further research into the potential immunogenic properties of PEG coatings as a function of molecular weight, functional group, surface density, NPs core properties, dosing frequency, etc., will undoubtedly result in more effective products (Suk etal. 2016).
12.1.1 Modification ofthePEG Surface
andLong-Circulation Properties
The typical structure of PEG is HO-(CH2CH2O)n-CH2CH2-OH, which includes a chemically inert polyether backbone and terminal hydroxyl groups that can be trig­gered for conjugation to various polymers and medicinal products. Poloxamers and poloxamines, which are amphiphilic block co-polymers made of blocks of hydro­philic PEG and hydrophobic polypropylene oxide (PPO), are additionally PEG derivatives frequently used for surface adsorption or entrapment modication. Covalent methods, such as grafting PEG chains onto the surface of the polymeric NPs, or co-polymers, in which PEG is covalently bonded to another type of poly­mer, can modify the surface of the NPs. PEG has the benets of being non-toxic and non-immunogenic, which led to the FDA of the United States approving it for use in individuals internally, a listing of inactive substances for parenteral and oral use, as well. Considering PEG is not biodegradable, it is available in a wide range of molecular weights up to several million daltons, which affects the rate at which the body can eliminate it.
348
N. Gupta et al.
PEG chains with a larger molecular weight shift from urine to fecal excretion. The protective (stealth) action of PEG is mainly due to the formation of a dense, hydrophilic cloud of long exible chains on the surface of the colloidal particles that reduces the hydrophobic interactions with the RES.The tethered and/or chemically anchored PEG chains can undergo spatial conformations, thus preventing the opso­nization of particles by the macrophages of the RES, which leads to preferential accumulation in the liver and spleen. PEG surface modication, therefore, enhances the circulation time of molecules and colloidal particles in the blood (Van Vlerken etal. 2007).
Today, PEGylation is crucial for imaging and diagnosing different body tissues. Macromolecular chelators such as polymers, antibodies, and recognition proteins are becoming more popular among chelators. PEGylation extends the period that paramagnetic chelates remain in the body. These chelates will then be eliminated from the body at slower rates through the kidney or liver than unmodied mole­cules, providing magnetic resonance to produce accurate images. PEG also serves as a linker between the targeting and diagnostic moieties, which signicantly impacts the biodistribution pattern of radiodiagnostics. PEG might assist in collect­ing more precise pictures in the case of protein-targeted diagnostics by reducing background noise brought on by nonspecic protein–protein interaction (Veronese and Pasut 2005).
To increase the effectiveness of drug and gene delivery to target cells and tissues, PEG is frequently used to coat the surface of NPs, a process known as “PEGylation.” The length of the systemic circulation is increased by PEG coatings on NPs, which protect the surface from opsonization, aggregation, and phagocytosis.
Systemically delivered medicines must circulate in the bloodstream for as long as possible to reach target tissues at sufcient concentrations. However, proteins and peptides rapidly break down and are removed from the blood; therefore, meth­ods for prolonging circulation duration are required. One such way is to coat the therapeutic’s surface with an inert polymer that prevents interactions with blood­stream constituents and gives it “stealth” qualities. Due to its long history of safety in human usage and FDA classication as Generally Regarded as Safe (GRAS), PEG is the most commonly utilized “stealth” polymer in the drug delivery industry (Li and Huang 2010).
Branched PEGs may provide steric repulsion due to the attachment of neighbor­ing PEG molecules, resulting in empty spaces on the surface, just enough to attract the nonspecic binding of opsonin proteins. These molecular weights of PEG have been reported to be between 1500 and 5000. To get the highest stealth qualities, a high density of short-chain PEG molecules is required, yet chains that are too short may be too rigid to give the necessary exibility (Karakoti etal. 2011).

12.1.2 Current Market Scenario

Many PEG-based medications have been developed, and a number of these have gained market acceptance. Due to vast clinical expertise, it has become possible to
12 PEGylated Nanocarriers forDiagnostic Applications
349
synthesize PEG prodrug conjugates with increased therapeutic efcacy while mini­mizing systemic toxicity. PEGylated products, such as PEGvisomant and certoli­zumab PEGol, demonstrated that PEGylated forms can be commercialized independently of the past commercialization of their non-PEGylated counterparts. In contrast, PEGylated drugs, such as PEGinterferon and PEGlgrastim, have proven their cost-effectiveness in the market. The market for therapeutic PEGylated proteins appears to have strong long-term potential. Because of its enormous clini­cal advantages, PEGylation is fundamental in delivering and targeting drugs and other bioactives. PEGylation is essential for achieving cellular targetability (Banerjee etal. 2012).
Few well-known PEGylated products in the market include PEG-interferon α-2a, PEG-Intron (PEG-interferon alpha-2b) for hepatitis (Herndon etal. 2012), Somavert (PEG-human growth hormone receptor antagonist) for acromegaly (Alconcel etal.
2011), Cimzia (certolizumabPEGol, PEGylated antihuman TNF-alpha Fab) for
rheumatoid arthritis (Lang 2008), Neulasta (PEGlgrastim, PEG-recombinant human granulocyte colony stimulating factor analogue) for neutropenia associated with cancer chemotherapy (Bence etal. 2002), PEG-erythropoietin (EPO) for ane­mia (Rubio 2015), Adagen (PEG-adenosine deaminase) for immunodeciency (Booth and Gaspar 2009), PEG-Hirudin for thrombosis, and Oncaspar (PEG aspara­ginase) for cancer treatment (Dinndorf etal. 2007).
More than 20 PEGylated nanocarriers have received clinical approval from the US FDA to date, including Doxil and Macugen, which are essential in managing cancer and neovascular age-related macular degeneration (Shi etal. 2021).
12.1.3 Ideal Properties ofPEGylated Nanocarriers
forDiagnostic Applications
PEG is an aqueous, safe, non-toxic, non-immunogenic, and non-antigenic polymer that is FDA-approved for human use. They are miscible with glycols, soluble in water, alcohol, acetone, and chloroform, and insoluble in ether. Due to its purported “stealth” qualities and biocompatibility, polyethylene glycol is frequently used in pharmaceutical delivery. The PEG-drug conjugates have several benets, including an extended residence in the body, delaying renal clearance, a reduced breakdown rate by metabolic enzymes, and a decreased level of protein immunogenicity. The viscosity of PEG solution with lower molecular weight is low and increases with the increase of molecular weight. PEG’s distinctive stability against oxidation, reduc­tion, and decomposition by acids, bases, relatively high temperatures, hydrogen peroxide, and sodium borohydride distinguishes it from other materials. Because PEG contains both hydrophilic and hydrophobic groups, it is a preferred solvent for green synthesis. Because of its capacity to exhibit phase separation under regulated conditions. The stealth features offered by PEG coatings have enhanced the enor­mous potential of nanoparticles in therapy, diagnostic imaging, treatment, and dis­ease prevention (Karakoti etal. 2011).
350
N. Gupta et al.
Nanoparticles with PEG coatings prevent surface aggregation, opsonization, and phagocytosis, extending circulation duration. Doxil, the rst PEGylated NPs prod­uct to receive FDA approval, was introduced in 1995. With a drug half-life of 72h and a circulation half-life of 36h, Doxil “Stealth” liposomes enhanced doxorubicin bioavailability about 90-fold at 1 week after injection compared to free drug (Working etal. 1994).
The therapeutic effectiveness of systemic chemotherapy is insufcient, and the systemic toxicity restricts the dosages of injectable drugs, thus reducing their thera­peutic efcacy. Creating a revolutionary system that permits early diagnosis and tailored therapy to address these shortcomings in present diagnostic and therapeutic techniques is essential.
12.2 PEGylated Nanocarriers inDiagnostic Applications
Recently, nanotechnology has drawn attention for its novel cancer diagnostic and therapeutic tool. These alternatives have been used to overcome the challenges that traditional diagnostic and therapeutic approaches offer. These difculties include toxicity, rapid drug release, and non-specicity. According to research done over the years, nanocarriers improve the bioavailability, specicity, and accumulation of medications at the target location. Their easily adjustable physical and chemical features can be attributed to these advancements. They are frequently altered in size and surface texture to improve their accumulation at the target areas and overall targeting capabilities. Nanocarriers are good candidates for uorescence-guided surgery and imaging methods due to their impressive uorescent characteristics. Biomimetic NPs, which effectively interact with complicated biological systems and imitate the functions of biological components, are another potential class of NPs (Zhang etal. 2020).
Researchers are examining nanotechnology-based tools and techniques as viable potential for the early diagnosis and treatment of cancer. Numerous studies have been done on enhancing targeted drug delivery and imaging while preserving ef­cacy. PEGylated nanocarriers have been utilized in recent times for the diagnosis and imaging of many diseases, including tumors. PEGylated magnetic NPs demon­strating magnetic characteristics are frequently used in magnetic targeting, mag­netic heating, and MRI contrast enhancement. Long-circulating NPs required for MRI and other theranostic applications are well-coated with PEGs (Illés etal. 2018).
A diagnostic tool that can characterize EPR is vital from a diagnostic standpoint. PEGylated NPs may be used to monitor drug release and long-term pharmacologi­cal efcacy, visualize and quantify biodistribution, and target site accumulation of NPs. Nanoparticles help characterize tumor angiogenesis, and very tiny NPs (less than 5 nm) can be utilized for molecular diagnostics for extravascular targets (Baetke etal. 2015).
The physicochemical characteristics of NPs make them suitable delivery systems for delivering drugs to brain tumors. The core or the surface of NPs can be coated with molecules, such as contrast agents or medications. As MRI contrast agents,
12 PEGylated Nanocarriers forDiagnostic Applications
351
numerous NPs have been developed with or without an organic material shell-like polyethylene glycol. NPs could be designed for imaging specic cell subpopula­tions, like endothelial cells or stem cells. NPs may advance the diagnosis, surgical treatment, and adjuvant therapy of brain tumors. NPs-based MRI contrast agents have the potential to make tumor areas visible that would not have been seen with conventional MRI, particularly at the tumor–brain interface (Cho etal. 2010).
Systemic chemotherapy exhibits an unfavorable biodistribution of anticancer medicines after systemic delivery, resulting in severe side effects, and has limited therapeutic efcacy. Additionally, systemic toxicity restricts the dosages of inject­able drugs, thereby lowering their therapeutic efcacy. Creating a revolutionary sys­tem that permits early diagnosis and tailored therapy to address these shortcomings in present diagnostic and therapeutic approaches is vital. The development of a method that allows early identication and focused treatment to enhance current procedures that have a high failure rate of colon cancer leading to metastases is crucial for improved management of colon cancer.
Colon tumors were successfully examined utilizing an near-infrared uores­cence (NIRF) imaging technique using a theranostic carrier system based on PEGylated hyaluronic acid NPs bearing NIRF imaging dye. Because of their remarkable tumor-targeting abilities, they demonstrated signicant inhibition of tumor growth with less systemic toxicity (Choi etal. 2012).

12.2.1 PEGylated Iron Oxide Nanoparticles

Polyethylene glycol has been extensively used on various nanoparticle systems to increase surface hydrophilicity and improve circulation half-life by decreasing interactions with blood proteins and mononuclear phagocyte system (MPS) cells. The use of PEGylated iron oxide NP ferrouids in invivo biomedical applications such as magnetic imaging resonance (MRI) contrast enhancement and cancer ther­apy by hyperthermia and/or targeted drug delivery is currently the subject of research. The magnetic characteristics of NPs could be utilized for drug delivery to improve the antitumor efcacy and lessen the systemic side effects of anticancer medications. Loaded PEGylated iron oxide NPs may be held in a cancer site and afterward released the drug there if an external localized magnetic eld is applied. The surface of iron oxide NPs has been transformed using PEG, which has been proven to increase biocompatibility and blood circulation rates. PEG surface coat­ing is utilized to prevent plasma adsorption and escape from the MPS (Shan etal. 2009).
Gadolinium, superparamagnetic iron oxides, ultrasmall (5–10nm) superpara­magnetic iron oxides, gadolinium-doped carbon nanotubes, quantum dots embed­ded paramagnetic micelles, and soft NPs are currently excellent magnetic contrast agents in the research eld. With their magnetic properties and contrast, PEGylated iron oxide NPs have already succeeded in biomedical areas such as diagnostics as a probe (MRI scanning) for discovering diseases or issues within the brain, car­diovascular system, liver, blood arteries, and other essential organs. PEGylated
352
N. Gupta et al.
iron oxide NPs have also been designed with advancements for carrying out mul­tiple operations in single-stage imaging. In recent times, PEGylated iron oxide NP-based nanohybrids were modied for partial thromboplastin time (PTT) and hyperthermia, where even small concentrations can effectively increase heat gen­eration at the tumor site and be employed for cellular treatments (Vallabani and Singh 2018).
PEGylated iron oxide nanoparticles with specic surface chemical characteris­tics have been widely exploited for several biological applications, including cell separation, tissue healing, targeted drug delivery, hyperthermia, and MRI contrast enhancement. Due to their low toxicity, size-dependent superparamagnetism, and biocompatibility with cells and tissue, superparamagnetic nature, PEGylated iron oxide NPs may, therefore, be able to increase contrast in MRI images more effec­tively than typical paramagnetic Gadolinium (Gd)-based contrast agents. Additionally, leaky vasculatures near tumors cause PEGylated iron oxide NPs with an appropriate particle size to accumulate in tumor sites through the enhanced per­meability and retention (EPR) effect. Developing PEGylated iron oxide NPs with controlled size and shape-restricted size distribution is preferable to gain advantage from their high-quality and regular imaging property in MRI and precise tumor targeting (Yue-Jian etal. 2010).
PEGylated iron oxide NPs can replace the currently utilized gadolinium-based contrast agents in MRI, which have demonstrated poor blood lifetime and low proton relaxation efciency. These limitations have led to greater administration doses, increasing human and environmental toxicity. Results indicate that these particles may be used for therapeutic applications and longitudinal imaging studies due to their high specic absorption rate (SAR) values. These biocompatible NPs are a potent tool for biomedical applications, primarily because of the current interest in non-invasive diagnostic assays based on real-time and long-term track­ing and monitoring of tagged cells (i.e., tumor-related macrophages) (Lazaro­Carrillo et al. 2020). There are many different biomedical and bioengineering applications for PEGylated iron oxide NPs, which belong to the family of magnetic materials known as ferrimagnetic materials. There are different types of iron oxide­based NPs like maghemite (y-Fe2O3), magnetite (Fe3O4), and mixed ferrites (MFe2O4), where M=Co, Mn, Ni, or Zn). PEGylated iron oxide NPs are produced after surface modication. They can be used for magnetic resonance imaging, magnetic particle imaging (MPI), targeted delivery of drugs, proteins, antibodies, and nucleic acids, separation of biomolecules, hyperthermia, biosensing, and tis­sue repair. These current exhaustive applications are brought about by magnetic characteristics and the fact that they may be synthesized in various forms and sizes. When exposed to an external magnetic eld, superparamagnetic iron oxide nanoparticles have signicant magnetic moments, and even when the magnetic eld is removed, there is no longer any magnetic moment. In preclinical and clini­cal trials, many iron oxide NPs have been examined, and a number of them have been commercialized.
12 PEGylated Nanocarriers forDiagnostic Applications
353
12.2.2 PEGylated Magnetic Nano Assemblies inDiagnosis
Magnetic nanocrystals made in an organic phase can be employed as contrast agents because of their well-dened crystal structures and excellent magnetic sensitivity. To increase their colloidal stability in the aqueous phase, additional surface modi­cation with a hydrophilic layer, for example, PEG, is needed because they are dis­seminated in the organic phase. PEG has a high hydrophilicity, a low cytotoxicity, and a high cell permeability. Specically, it helps reduce nonspecic interactions with serum proteins by creating hydrogen bonds with water molecules, which extends the duration that the substance is in circulation in the blood. For PEG-based materials, there are two primary surface modication techniques. The rst one is the exchange technique, in which the hydrophobic ligand on the magnetic nanocrystal (MNC) surface is replaced with PEG at elevated temperatures, and the second tech­nique is the addition technique, in which a hydrophobic MNC’s surface is covered with the emulsion technique using a PEG-based amphiphilic polymer as a surfac­tant (Fig.12.2).
Using this addition technique, it is possible to load MNCs, uorescent materials, and drugs together to create a multifunctional nanocomposite. It is challenging to obtain constantly sized NPs, particularly nanoclusters. Because it also triggers the transition between the super magnetic–ferrimagnetic transitions, growing the size of MNCs to increase the saturation magnetization has limitations. Instead, it has been suggested that creating magnetic nanoclusters successfully maintains super­paramagnetic behavior with high magnetization.
Due to their high magnetic susceptibility, low coercive force, and high magnetic characteristics, magnetic NPs made up of several single MNCs are very appealing. Due to the PEG molecules on the particle surface (PEGylation effect), the PEGylated MNs displayed better durability in an aqueous phase for a longer period of time than those of a commercial MRI contrast agent, as well as an appropriate MRI contrast
Fig. 12.2 An illustration of a magnetic nanoparticle structure for targeting ligands, uorophores, and responsive elements
354
N. Gupta et al.
effect due to the magnetic clustering effect. Additionally, invivo tests conrm that PEGylated MNCs have a potential value as MRI agents for cancer diagnosis (Kang etal. 2019). An external magnetic eld can inuence magnetic NPs, indicating their ability to be site-specic. MNPs are an excellent choice for the simultaneous deliv­ery of diagnostic and treatment, commonly known as theranostics; due to their imaging capabilities and magnetic characteristics, MNPs have a higher theranostic potential than liposomes or other polymer-based nanoparticles. Owing to their capacity to be simultaneously directed, visualized, and heated by external magnetic elds, MNPs are useful in theranostics (Alromi etal. 2021). Magnetic nanoparticles are being developed and employed in magnetic resonance imaging as contrast­enhancing agents for diagnosing a wide range of ailments, including cancer, cardio­vascular disease, and neurological disorders.
Magnetic NPs that have been radioactively labeled have been shown to be highly effective at diagnosing cancer. Compared to conventional imaging methods, it has few key advantages. Due to the EPR effect, magnetic NPs labelled with radioactive tracers have precision targeting; they also have a high surface-to-volume ratio, enabling the use of high-density radioactive labels; and they are capable of comple­mentary multimodal imaging, such as integrated imaging using various radionu­clide nanoparticles.
Magnetic uorescent nanocomposites that are superparamagnetic and uores­cent have been developed by integrating magnetic NPs with uorescent elements. The efciency of cell imaging is signicantly increased when the magnetic uores­cent nanocomposites are introduced to living cells because the uorescence can be monitored and programmed to be enriched at the desired area when an external magnetic eld is applied.
In addition to having the general features of NPs, magnetic NPs also possess magnetic capabilities, which have recently attracted the attention of researchers in the eld of nanomedicine. Due to their special characteristics, magnetics are exten­sively employed in biomedicine, drug-gene delivery, magnetic resonance imaging, molecular probes, tumor detection, tumor therapy, and other domains. Magnetic NPs will be utilized more frequently in tumor diagnosis and treatment as nanotech­nology advances (Bian etal. 2021).
12.2.3 PEGylated Quantum Dots inTargeted Tissue Imaging
PEGylated quantum dots (QDs) are uorescent NPs, distinguished by their extraor­dinary optical characteristics, including strong uorescence emission, photostabil­ity, a compact emission spectrum, and a wide excitation wavelength. They are an intriguing option for applications involving bioimaging due to such features. The PEG coating helps them escape plasma protein adsorption and RES clearance, which prolongs the blood circulation of quantum dots in the body and increases the possibility that they will reach to their target area successfully. PEGylated QDs is currently a dynamic delivery system for diagnostic applications (Fig.12.3).
12 PEGylated Nanocarriers forDiagnostic Applications
Fig. 12.3 Targeting of quantum dots
355
Long-term dynamic imaging is a perfect application for PEGylated QDs because of their optical characteristics, specically their capacity to emit uorescence in the near-infrared (NIR) range and their resistance to photobleaching. As a result, they could be utilized in uorescence-guided surgery (FGS) to speed up tumor removal and produce negative surgical margins and therefore enhancing the prognosis of a patient. In surgical oncology, FGS is a real-time intraoperative procedure, which is designed to highlight tumors during surgical resection to speed up tumor excision and provide negative tumor margins. The prognosis of a patient must be improved by complete tumor excision with negative margins. Additionally, PEGylated QDs have the ability to generate uorescence in the near-infrared spectrum, which is of signicant relevance to uorescence-guided surgery (Dirheimer etal. 2022).
They provide enhanced uorescence intensity, superior photobleaching resis­tance, size-tunable light emission, and the capacity to generate different uorescent colors from a single excitation source. The optimum surface for coupling with a range of targets, such as antibodies, peptides, and several other small molecules, is offered by QDs. They might thus present effective alternatives to the more sensitive and focused cancer molecular targeting and bioimaging detection methods currently in use. Cancer imaging has evolved greatly since Gao intravenously administered PEG-coated QDs functionalized with antibodies to prostate-specic membrane antigen. Furthermore, the ability to resist bleaching for extended periods enables the collection of sharp, well-contrasted images that are particularly helpful for 3D opti­cal sectioning of tumors and the environment around them because bleaching of uorophores hinders the accurate reconstruction of 3D structures.
Additionally, their long-term stability, excellent brightness, wider and continu­ous excitation spectrum, and deep penetration make them the perfect choice for invivo cancer diagnostics and bio-imaging. Some of the goals of creating new and improved cancer diagnostics and imaging probes have already been realized because of the rapid advancement of QDs technology. The active targeting of tumors is now achievable due to their characteristics and effective conjugation with biomolecules.
356
N. Gupta et al.
Despite the potential and large application of QDs in cancer imaging and detection to date, there are still obstacles to be cleared in terms of improving specicity, enhancing sensitivity, and reducing QDs toxicity before clinical applications may advance (Liang etal. 2021).
Aptamer-conjugated PEGylated QDs is recent advancement for targeting epider­mal growth factor receptor variant III for uorescence imaging of glioma. In glioma patients, the degree of resection plays a substantial predictive role. However, because tumors are naturally inltrative, it is challenging to identify the maximal safe resection level. Recently, FGS, a novel technique for safely removing gliomas, has emerged. PEGylated QDs have a number of exceptional benets, including chemical stability, broad absorption with narrow emission spectra, high quantum uorescence yield, and water solubility. QDs have signicantly increased biocom­patibility when their shell is made of ZnS and coated with PEG.Additionally, the PEG coating helps them to evade plasma protein adsorption and RES clearance, which increases the likelihood that they will reach their intended area.
One of the most well-known near-infrared imaging probes was made using PEGylated Silver Sulphide QDs with special optical properties. They showed much­improved blood ow and tumor accumulation invivo when compared to the origi­nal ones, making them great candidates for use as tumor imaging probes.
High-resolution whole-body blood vessel imaging of living mice was accom­plished, and near-infrared imaging was also used to examine the biodistribution of QDs. The wide excitation range, resistance to photobleaching, and lack of toxic heavy metal components that PEGylated Silver Sulphide QDs display are all crucial for bioimaging. In addition to these fundamental qualities, surface features were essential for invivo applications since they may directly affect the blood ow and biodistribution of the NPs. PEG grafting is one of the most popular methods for extending nanoparticle circulation and enhancing tumor accumulation by lowering nonspecic binding to proteins and cells. As a result, PEGylated Ag2S QDs offer a uniform structure for invivo imaging using quantum dots (Lu etal. 2020).
12.2.4 PEGylated Gold NPs forImaging Applications
PEGylated Gold nanoparticles (PEG-AuNPs) are highly biocompatible and have a variety of potential biological applications. PEG-AuNPs, which have had their sur­face modied with PEG, can be used to conjugate them with a variety of biological molecules. Unique features of gold nanoparticles include their small size, excellent biocompatibility, low toxicity, basic surface chemistry, and ease of surface modi­cation. PEG-AuNPs are up-and-coming prospects for biomedical use with a wide range of biological applications, including as biosensors and drug delivery vectors for chemotherapy and radiation therapy for cancer.
However, due to absorption and rapid clearance by the RES, specically macro­phages, administration of nanoparticles to target tumor locations is typically con­strained. To prevent the absorption of opsonin proteins, PEG-coated NPs (PEGylation) can provide a hydrophilic protective layer consequently reducing